Economic Impacts and Pricing Strategies Surrounding Biosimilars

Video content above is prompted by the following:

• What economic impacts do biosimilars have in different delivery channels (inpatient, self-administered outpatient, outpatient infusion)?
• How do pricing strategies for biosimilars, such as the high and low list prices of adalimumab biosimilars, affect their market penetration and adoption?
  • How do biosimilar pricing strategies affect patient access and affordability?
  • Are there more effective pricing models that could be adopted?
  • Are there certain customer subtypes that will want a rebate drive model vs. those want a rebate driven model vs. a WAC driven model?